These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Emerging role of immunotherapy in the management of prostate cancer. Slovin SF Oncology (Williston Park); 2007 Mar; 21(3):326-33; discussion 334, 338, 346-8. PubMed ID: 17447437 [TBL] [Abstract][Full Text] [Related]
3. Sex Hormones and Anticancer Immunity. Özdemir BC; Dotto GP Clin Cancer Res; 2019 Aug; 25(15):4603-4610. PubMed ID: 30890551 [TBL] [Abstract][Full Text] [Related]
5. Advances in specific immunotherapy for prostate cancer. Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335 [TBL] [Abstract][Full Text] [Related]
6. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy. Hwang C; Sanda MG Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762 [TBL] [Abstract][Full Text] [Related]
7. Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer. Silvestri I; Cattarino S; Aglianò AM; Collalti G; Sciarra A Biomed Res Int; 2015; 2015():794968. PubMed ID: 26161414 [TBL] [Abstract][Full Text] [Related]
8. Recent advances in immunotherapy for the treatment of prostate cancer. Sonpavde G; Agarwal N; Choueiri TK; Kantoff PW Expert Opin Biol Ther; 2011 Aug; 11(8):997-1009. PubMed ID: 21675925 [TBL] [Abstract][Full Text] [Related]
9. Current immunotherapeutic strategies in prostate cancer. Grosso JF; Drake CG Surg Oncol Clin N Am; 2007 Oct; 16(4):861-71, x. PubMed ID: 18022549 [TBL] [Abstract][Full Text] [Related]
10. Pitfalls or promise in prostate cancer immunotherapy-which is winning? Slovin SF Cancer J; 2008; 14(1):26-34. PubMed ID: 18303480 [TBL] [Abstract][Full Text] [Related]
12. Intermittent endocrine therapy and its potential for chemoprevention of prostate cancer. Oliver RT; Gallagher CJ Cancer Surv; 1995; 23():191-207. PubMed ID: 7621458 [TBL] [Abstract][Full Text] [Related]
13. Immunotherapy and prostate cancer. Kaminski JM; Summers JB; Ward MB; Huber MR; Minev B Cancer Treat Rev; 2003 Jun; 29(3):199-209. PubMed ID: 12787714 [TBL] [Abstract][Full Text] [Related]
14. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice. Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311 [TBL] [Abstract][Full Text] [Related]
15. Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting. Miyahira AK; Kissick HT; Bishop JL; Takeda DY; Barbieri CE; Simons JW; Pienta KJ; Soule HR Prostate; 2015 Mar; 75(4):337-47. PubMed ID: 25358693 [TBL] [Abstract][Full Text] [Related]
16. Tribulations or triumphs in prostate cancer immunotherapy: on the road to victory? Slovin SF Expert Rev Anticancer Ther; 2008 Mar; 8(3):465-74. PubMed ID: 18366293 [TBL] [Abstract][Full Text] [Related]
17. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer. Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069 [TBL] [Abstract][Full Text] [Related]
18. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer. Lubaroff DM; Karan D Adv Drug Deliv Rev; 2009 Mar; 61(3):268-74. PubMed ID: 19166887 [TBL] [Abstract][Full Text] [Related]
19. Development of novel immune interventions for prostate cancer. Agarwal N; Padmanabh S; Vogelzang NJ Clin Genitourin Cancer; 2012 Jun; 10(2):84-92. PubMed ID: 22409862 [TBL] [Abstract][Full Text] [Related]
20. Prostate cancer: genes, environment, immunity and the use of immunotherapy. Karan D; Thrasher JB; Lubaroff D Prostate Cancer Prostatic Dis; 2008; 11(3):230-6. PubMed ID: 18283297 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]